Document is current

Article History

Accepted: 15 April 2025

First Online: 7 May 2025

Declarations

:

: MCAS has received lecture fees from Pfizer. MB has served as speaker and/or consultant for Sandoz-Hexal, NovoNordisk, Pfizer, Roche, IDS, ConsilientHealth and Pharmanovia. GJ has served as a consultant for Novo Nordisk, Shire, and Astra Zeneca and has received lecture fees from Novo Nordisk, Shire/Takeda, Pfizer and Pharmanova. AG received lecture fees from Pfizer, Ascendis Pharma and Novo Nordisk. BB has served as an occasional consultant for Ascendis, Novo Nordisk and as PI of a research grant to Massachusetts General Hospital from Ascendis. CCS received speaker fees from Novo Nordisk. AH has served as a consultant for Ascendis. PB is a consultant for, and has received honoraria from Novo Nordisk, Ascendis Pharma, BioMarin Pharmaceutical, Cavalry Biosciences, Ipsen Biopharmaceuticals, and Upsher-Smith Laboratories. PC has received unrestricted research and educational grants from Ipsen, Novo-Nordisk, and Pfizer on behalf of the Service of Endocrinology and Reproductive Diseases, Hôpitaux Universitaires Paris-Saclay and Association Recherche Endocrinologie Bicêtre, has served as principal investigator for clinical trials funded by Prolor Biotech and Æterna Zentaris, has been on advisory boards for Æterna Zentaris and Pharmanovia and gave lectures for Ipsen, Pfizer and Consilient Health. All the fees and honoraria are paid to his Institution or Research Association. EC has received grants and lecture and consulting fees from Novo Nordisk and Pfizer. SC has served as a consultant for Crinetics, Novo-Nordisk and Sandoz, and has received lecture fees from Sanofi. PEC has served as a consultant to Lumos Pharma US and has received grants from Novo Nordisk and lecture fees from Merck. MF has received research support to the Oregon Health Sciences University from Ascendis and consulting fees from Novo Nordisk for occasional scientific consulting. GA is editor-in-chief of Pituitary, CH has received lecture fees from Sandoz, Pfizer and Novo Nordisk. AJ received speaker fees from Novo Nordisk, IPSEN and Sandoz, and received unrestricted grant support from Novo Nordisk and Lundbeck. KKM has received study medication and investigator-initiated research grants from Amgen and has equity in Bristol-Myers Squibb (BMS), GE Healthcare Technologies, Boston Scientific, and Becton Dickinson. SM has served as a consultant for Novo Nordisk. SJCMMN has occasionally served as speaker or consultant for Novo- Nordisk, Pfizer and Pharmanovia. NK has served as a speaker, investigator and Scientific Advisory Board for Pfizer. LS has served as speaker and/or consultant for Sandoz-Hexal, Novo Nordisk, Merck, and Pfizer. KS has received lecture fees from Pfizer and Novo Nordisk and has served as a consultant for Pharmanovia and Novo Nordisk. PFCS has received travel grants and speaker fees from Pfizer, Merck-Serono, Novo Nordisk, Sandoz and Biomarin. CJS has occasionally served as speaker or consultant for Sandoz-Hexal, Novo Nordisk, Ascendis, Pfizer, Consilient Health and Pharmanovia. HVS has received an investigator-initiated research grant from Pfizer and Rhythm and has served as a consultant for Rhythm. KCJY has received research grants to Barrow Neurological Institute from Ascendis, received lecture fees from Novo Nordisk and Ascendis and served as an occasional advisory board member for Novo Nordisk and Ascendis. JOLJ has received grants and consulting fees from Novo Nordisk and Pfizer and has been on an advisory board for Pharmanovia. In addition, JOLJ is an associate Editor for The Journal of Clinical Endocrinology & Metabolism and played no role in the Journal’s evaluation of the manuscript. The other authors have nothing to declare.